PharmAthene to Present Data for Protexia and Valortim at HHS PHEMCE Stakeholders Workshop 2008

ANNAPOLIS, Md., September 18, 2008 /PRNewswire-FirstCall/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will present two poster presentations and an oral presentation on its Protexia(R) and Valortim(R) medical countermeasures programs at the upcoming HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 / BARDA Industry Day, being held in Alexandria, VA September 24 -26, 2008.

Protexia(R), a recombinant version of human butyrylcholinesterase (BChE), is being developed as a pre- and post-exposure therapy for casualties on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with Medarex, Inc., is a fully human monoclonal antibody designed to treat and protect against inhalational anthrax.

The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 and BARDA Industry Day will bring together public and private sector stakeholders for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

 

    -- SparVax(TM) - a second generation recombinant protective antigen (rPA)
       anthrax vaccine
    -- Third generation rPA anthrax vaccine
    -- Valortim(R) - a fully human monoclonal antibody for the prevention and
       treatment of anthrax infection
    -- Protexia(R) - a novel bioscavenger for the prevention and treatment of
       morbidity and mortality associated with exposure to chemical nerve
       agents
    -- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit http://www.PharmAthene.com.

CONTACT: Stacey Jurchison of PharmAthene, Inc., +1-410-269-2610, JurichsonS@PharmAthene.com

Web site: http://www.pharmathene.com/

Ticker Symbol: (AMEX:PIP)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: September 2008

View comments

Hide
(web4)